RxDoctor Payments Data

David Diamant, MD

Family Medicine · Greenville, SCNPI 1003221623

Payments from drug & device makers

$8,982in general payments, 2019–2025

Across 543 payments — averaging $16.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$781
  • Pfizer$719
  • AbbVie$656
  • GSK$590
  • Amgen$511
  • plus $5K from 39 others

What the payments were for

  • Food & beverage$8,982100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,982 in reported general payments places this provider in the 90th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$148,313
Medicare patients
228
Services billed
2,119

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin125$144,235
OzempicSemaglutide65$81,910
EliquisApixaban69$66,232
RybelsusSemaglutide29$59,370
FarxigaDapagliflozin Propanediol60$43,435
TrulicityDulaglutide22$27,971
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$24,337
XareltoRivaroxaban19$22,026
EntrestoSacubitril/Valsartan12$19,502
JanuviaSitagliptin Phosphate17$12,948
MyrbetriqMirabegron11$9,363
Spiriva RespimatTiotropium Bromide12$6,253
Breo ElliptaFluticasone/Vilanterol12$5,010
Atorvastatin Calcium446$3,465
Albuterol Sulfate HfaAlbuterol Sulfate95$2,767

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Spiriva Respimat$356$150,489137 claims
Novo NordiskOzempic, Rybelsus$1,131$141,28194 claims
PfizerEliquis$719$66,23269 claims
AstraZenecaFarxiga$781$43,43560 claims
GSKTrelegy Ellipta, Breo Ellipta$590$29,34745 claims
Lilly USA, LLCTrulicity$496$27,97122 claims
Johnson & JohnsonXarelto$277$22,02619 claims
NovartisEntresto$189$19,50212 claims
MerckJanuvia$110$12,94817 claims
Astellas Pharma US IncMyrbetriq$207$9,36311 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$12$2,157237 claims
AbbVieSynthroid$656$1,22516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →